[Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].

Abstract

BACKGROUND:

Post kidney transplantation erythrocytosis is a frequent complication in male subjects. in our experience, it occurs in approximately 20% of transplant patients recciving cyclosporine inununosuppression therapy.

METHODS:

Twenty-two patients with post kidney transplantation erythrocytosis were treated using ACE-inhibitors (lisinopril) at a dose of 2-5-5 mg/day for a mean period of 15 months. Owing to tbe onset of collateral effects, 27% of these patients requested the conversion of ACE into angiotensin II receptor antagonists (AII). Twenty out of 22 patients were male (90%).

RESULTS:

Treatment resulted in a 15% reduction of hematocrit values compared to basal levels, which remained stable over time. No collateral effects were recorded, either for the kidneys or in terms of hypotension.

CONCLUSIONS:

ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like Iosartan at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE).

• Authors: W Morale, C Puliatti, P Veroux, M Veroux, C Valvo, D Cappello, D Puliatti, L Francesco
• Journal: Minerva urologica e nefrologica = The Italian journal of urology and nephrology (Minerva Urol Nefrol) Vol. 54 Issue 3 Pg. 189-92 (Sep 2002) ISSN: 0393-2249 [Print] Italy
• Vernacular Title: Trattamento dell'eritrocitosi post-trapianto (PTE) renale con gli ACE-inibitori.
• PMID: 12384621 (Publication Type: English Abstract, Journal Article)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Lisinopril

Topics

• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Female
• Humans
• Kidney Transplantation (adverse effects)
• Lisinopril (therapeutic use)
• Male
• Polycythemia (drug therapy, etiology)
• Retrospective Studies